Jens Schmidt
Overview
Explore the profile of Jens Schmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
4331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Conticini E, Dourado E, Bottazzi F, Cardelli C, Bruno L, Schmidt J, et al.
Clin Exp Rheumatol
. 2024 Mar;
42(2):213-224.
PMID: 38488099
Idiopathic inflammatory myopathies are a group of rare, autoimmune, diseases typically involving striate muscle and also variously affecting several other systems or organs, such as joints, skin, lungs, heart and...
12.
Loganathan A, Zanframundo G, Yoshida A, Faghihi-Kashani S, Bauer Ventura I, Dourado E, et al.
Clin Exp Rheumatol
. 2024 Mar;
42(2):277-287.
PMID: 38488094
Objectives: The CLASS (Classification Criteria of Anti-Synthetase Syndrome) project is a large international multicentre study that aims to create the first data-driven anti-synthetase syndrome (ASSD) classification criteria. Identifying anti-aminoacyl tRNA...
13.
Oldroyd A, Callen J, Chinoy H, Chung L, Fiorentino D, Gordon P, et al.
Nat Rev Rheumatol
. 2023 Nov;
19(12):805-817.
PMID: 37945774
Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within the 3 years preceding and following IIM onset. Evidence- and consensus-based recommendations for IIM-associated cancer screening can...
14.
Wilcke H, Glaubitz S, Kuck F, Anten C, Liebetanz D, Schmidt J, et al.
BMC Neurol
. 2023 Oct;
23(1):366.
PMID: 37817097
Background: Myasthenia gravis (MG) affects individuals as a chronic autoimmune disease for many years. Commonly, chronic diseases significantly reduce the patients' quality of life. Aiming to improve the future quality...
15.
Carstens P, Mullar L, Wrede A, Zechel S, Wachowski M, Brandis A, et al.
Front Immunol
. 2023 Sep;
14:1177721.
PMID: 37731487
Introduction: We aimed to identify B-cell-mediated immunomechanisms in inclusion body myositis (IBM) and polymyositis (PM) as part of the complex pathophysiology. Materials And Methods: Human primary myotube cultures were derived...
16.
Hum R, Lilleker J, Lamb J, Oldroyd A, Wang G, Wedderburn L, et al.
Rheumatology (Oxford)
. 2023 Sep;
63(8):2093-2100.
PMID: 37698987
Objectives: To compare clinical characteristics, including the frequency of cutaneous, extramuscular manifestations and malignancy, between adults with anti-synthetase syndrome (ASyS) and DM. Methods: Using data regarding adults from the MYONET...
17.
Kummer K, Bertram I, Zechel S, Hoffmann D, Schmidt J
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37445853
Inclusion body myositis (IBM) is a chronic, mostly treatment-resistant, inflammatory myopathy with a pathology that centers around specific interactions between inflammation and protein accumulation. The study aimed to identify the...
18.
Schmidt J, Muller-Felber W
Nervenarzt
. 2023 May;
94(6):510-518.
PMID: 37222759
Background: Inflammatory diseases of the skeletal muscle are important, often severe diseases with a considerable impact on the quality of life. In addition to muscle weakness there is often involvement...
19.
Dourado E, Bottazzi F, Cardelli C, Conticini E, Schmidt J, Cavagna L, et al.
Clin Exp Rheumatol
. 2023 Feb;
41(2):199-213.
PMID: 36826800
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of disorders in which chronic inflammation of the skeletal muscle, leading to muscle weakness, is a common feature. Different phenotypes have been...
20.
Roy B, Lucchini M, Lilleker J, Goyal N, Naddaf E, Adler B, et al.
Clin Exp Rheumatol
. 2023 Feb;
41(2):370-378.
PMID: 36762744
Objectives: Sporadic inclusion body myositis (IBM) is a debilitating idiopathic inflammatory myopathy (IIM) which affects hand function, ambulation, and swallowing. There is no approved pharmacological therapy for IBM, and there...